SCHEMBL4286923

SCHEMBL4286923

COc1ccc(C2(N)C=CNC(N)=N2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.40
BACE1 P56817 3/20 0.39
BACE2 Q9Y5Z0 1/20 0.39
CYP3A4 P08684 3/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
MAPK1 P28482 1/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
TSHR P16473 1/20 0.37
METAP1 P53582 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4278742 0.82 ACHE (0.31) MAOBMAOA
SCHEMBL2846013 0.80 BACE1 (0.42) BACE1BACE2CYP2D6CYP2C9LMNA
SCHEMBL4292713 0.79 TAAR1 (0.35) KDM4EHPGDCYP2C19RAB9ATDP1
SCHEMBL4281843 0.79 KDM4E (0.35) BACE1BACE2KDM4ENPC1RAB9A
SCHEMBL14358974 0.75 BACE1 (0.42) TRPA1BACE1BACE2CYP3A4KDM4E
SCHEMBL3301272 0.72 BACE1 (0.39) BACE1
SCHEMBL2915737 0.70 MAOA (0.35) BACE1MAOA
SCHEMBL4286812 0.67 MAPT (0.46) CYP3A4KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL1172089 0.67 BACE1 (0.39) BACE1BACE2CYP3A4KDM4ECYP2C19
SCHEMBL4286926 0.66 TDP1 (0.37) BACE1BACE2CYP3A4KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US claimed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT TRPA1 4147/4885BACE1 3568/4885BACE2 3023/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT TRPA1 3724/4885BACE1 2395/4885BACE2 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.